Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy

World Journal of Surgical Oncology

Volumn 12, Issue 1, 2014, Pages

  Sun, Zhipeng ^a   Zhang, Nengwei ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

CA125; CA19 9; CA72 4; CEA; Gastric cancer; Neoadjuvant chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; CA-72-4 ANTIGEN; PLATINUM COMPLEX; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; ANEMIA; ANOREXIA; ARTICLE; BLOOD SAMPLING; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EVALUATION; FATIGUE; FEMALE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SENSORY NEUROPATHY; STOMACH CANCER; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; ADENOCARCINOMA; BLOOD; FOLLOW UP; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; NEOADJUVANT THERAPY; PATHOLOGY; PROGNOSIS; SECONDARY; STOMACH NEOPLASMS; TUMOR INVASION; TUMOR RECURRENCE;

ADENOCARCINOMA; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CA-125 ANTIGEN; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 84924212402     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-12-397     Document Type: Article

References (36)

1. Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24:2137-2150. 10.1200/JCO.2005.05.2308
2. Wang CS, Chao TC, Jan YY: Benefits of palliative surgery for far-advanced gastric cancer. Chang Gung Med J 2002, 25:792-802.
3. Fink U, Stein HJ, Schuhmacher C, Wilke HJ: Neoadjuvant chemotherapy for gastric cancer: update. World J Surg 1995, 19:509-516. 10.1007/BF00294711
4. Niederhuber JE: Neoadjuvant therapy. Ann Surg 1999, 229:309-312. 10.1097/00000658-199903000-00002
5. Sakamoto J: Neoadjuvant chemotherapy: a standard treatment for locally advanced gastric cancer in the near future? Gastric Cancer 2003, 6:131-133. 10.1007/s10120-003-0254-3
6. Mezhir JJ, Tang LH, Coit DG: Neoadjuvant therapy of locally advanced gastric cancer. J Surg Oncol 2010, 101:305-314. 10.1002/jso.21483
7. 18 F-fluorodeoxyglucose- positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer. J Surg Oncol 2010, 102:135-140. 10.1002/jso.21592
8. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ: Gastric cancer. Lancet 2009, 374:477-490. 10.1016/S0140-6736(09)60617-6
9. Yamao T, Kai S, Kazami A: Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer. Jpn J Clin Oncol 1999, 29:550-555. 10.1093/jjco/29.11.550
10. Edge SB, Compton CC: The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010, 17:1471-1474. 10.1245/s10434-010-0985-4
11. Washington K: 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol 2010, 17:3077-3079. 10.1245/s10434-010-1362-z
12. Edge SBBD, Compton CC, Fritz AG, Greene FL, Trotti A: (Eds): AJCC Cancer Staging Manual. 7th edition. New York, NY: Springer; 2010.
13. Eisenhauer EA, Therasse P, Bogaerts J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247. 10.1016/j.ejca.2008.10.026
14. Ajani JA, Ota DM, Jessup JM: Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy. Cancer 1991, 68:1501-1506. 10.1002/1097-0142(19911001)68:7<1501::AID-CNCR2820680706>3.0.CO;2-L
15. Becker K, Mueller JD, Schulmacher C: Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003, 98:1521-1530. 10.1002/cncr.11660
16. Ninomiya Y, Yanagisawa A, Kato Y: Histological indications of a favorable prognosis with far-advanced gastric carcinomas after preoperative chemotherapy. J Cancer Res Clin Oncol 1999, 125:699-706. 10.1007/s004320050337
17. Moehler M, Schimanski CC, Gockel I: (Neo)adjuvant strategies of advanced gastric carcinoma: time for a change? Dig Dis 2004, 22:345-350. 10.1159/000083597
18. Gaspar MJ, Arribas I, Coca MC, Diez-Alonso M: Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma. Tumour Biol 2001, 22:318-322. 10.1159/000050633
19. Tocchi A, Costa G, Lepre L: The role of serum and gastric juice levels of carcinoembryonic antigen, CA19.9 and CA72.4 in patients with gastric cancer. J Cancer Res Clin Oncol 1998, 124:450-455. 10.1007/s004320050198
20. Ychou M, Duffour J, Kramar A: Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Dis Markers 2000, 16:105-110. 10.1155/2000/595492
21. Ucar E, Semerci E, Ustun H: Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer. Adv Ther 2008, 25:1075-1084. 10.1007/s12325-008-0100-4
22. Marrelli D, Roviello F, De Stefano A: Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma. Oncology 1999, 57:55-62. 10.1159/000012001
23. Marrelli D, Pinto E, De Stefano A: Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer. Am J Surg 2001, 181:16-19. 10.1016/S0002-9610(00)00549-3
24. Byrne DJ, Browning MC, Cuschieri A: CA72-4: a new tumour marker for gastric cancer. Br J Surg 1990, 77:1010-1013. 10.1002/bjs.1800770918
25. Spila A, Roselli M, Cosimelli M: Clinical utility of CA 72-4 serum marker in the staging and immediate post-surgical management of gastric cancer patients. Anticancer Res 1996, 16:2241-2247.
26. Carpelan-Holmstrom M, Louhimo J, Stenman UH: CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res 2002, 22:2311-2316.
27. Hamazoe R, Maeta M, Matsui T: Ca72-4 compared with carcinoembryonic antigen as a tumor-marker for gastric-cancer. Eur J Cancer 1992, 28A:1351-1354.
28. Gonzalez A, Vizoso F, Allende MT: Preoperative CEA and TAG-72 serum levels as prognostic indicators in resectable gastric carcinoma. Int J Biol Markers 1996, 11:165-171.
29. Ikeguchi M, Katano K, Saitou H: Pre-operative serum levels of CA72-4 in patients with gastric adenocarcinoma. Hepato-Gastroenterology 1997, 44:866-871.
30. Iwanicki-Caron I, Di Fiore F, Roque I: Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer. J Clin Oncol 2008, 26:3681-3686. 10.1200/JCO.2007.15.0904
31. Hess V, Glimelius B, Grawe P: CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol 2008, 9:132-138. 10.1016/S1470-2045(08)70001-9
32. Katz MH, Varadhachary GR, Fleming JB: Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol 2010, 17:1794-1801. 10.1245/s10434-010-0943-1
33. Precht LM, Lowe KA, Atwood M, Beatty JD: Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival. Breast J 2010, 16:362-368.
34. Kang S, Kim TJ, Seo SS: Interaction between preoperative CA-125 level and survival benefit of neoadjuvant chemotherapy in advanced epithelial ovarian cancer. Gynecol Oncol 2010, 120:18-22.
35. Wanebo JH, Stearns M, Schwartz MK: Use of CEA as an indicator of early recurrence and as a guide to a selected second-look procedure in patients with colorectal cancer. Ann Surg 1978, 188:481-493. 10.1097/00000658-197810000-00006
36. Attiyeh FF, Stearns MW Jr: Second-look laparotomy based on CEA elevations in colorectal cancer. Cancer 1981, 47:2119-2125. 10.1002/1097-0142(19810501)47:9<2119::AID-CNCR2820470903>3.0.CO;2-7